Introducing a New Lens Transplant Approved by FDA
A revolutionary new intraocular lens has been approved by the U.S. Food and Drug Administration for the treatment of cataracts, the first and only lens in the United States to provide a full range of continuous high-quality vision following cataract surgery.
The TECNIS Symfony® Intraocular Lens is a breakthrough in the field of optical lenses, engineered to reduce the effects of presbyopia (nearsightedness) by helping people focus clearly on near objects while still maintaining excellent distance vision – something no other surgically implanted lens has been able to do.
Cataracts are the most common cause of vision loss in people over 40, resulting in blurred or foggy vision and even blindness. Nearly 4 million cataract surgeries are performed each year in the U.S., and that number is expected to increase. In addition, cataracts affect more than just seniors; an estimated 1 in 4 cataract surgeries are performed on people younger than 65.
During cataract surgery, the natural lens of the eye is removed and replaced with an artificial intraocular lens (IOL). Most IOLs are monofocal, meaning they can focus at a single distance, usually far. To focus on near objects, patients must use reading glasses. In contrast, the new Symfony lens allows focusing at near and far distances without loss of clarity, reducing or removing the need for additional eyewear.
Clinical studies have shown that the new lens provides high-quality vision in day and night conditions with very little halo or glare, often perceived as rings or blurring around bright lights. A version of the lens is also available with correction for astigmatism.
If you have cataracts, ask your ophthalmologist about your options. If surgery is recommended, this new type of intraocular lens may be right for you.
April 5, 2017